Differences in Motivators, Barriers, and Incentives between Black and White Older Adults for Participation in Alzheimer’s Disease Biomarker Research
medRxiv (Cold Spring Harbor Laboratory)(2022)
摘要
Introduction The study aimed to identify strategies to increase older Black adults’ participation in Alzheimer’s disease (AD) biomarker research studies.
Methods 399 community-dwelling Black and White older adults (age ≥ 55) who had never participated in AD research completed a survey about their perceptions of AD research involving blood draw, MRI, and PET.
Results Although most participants expressed interest in AD biomarker research (Black participants: 63.0%, White participants: 80.6%), Black participants were significantly more hesitant than White participants (28.9% vs 15.1%), were more concerned about study risks, (30.8% vs. 11.1%) and perceived multiple barriers to participating in brain scans. Lack of information was perceived as a barrier to participation across groups (45.8%) and return of study results was perceived as a participation incentive (78.9-85.7%) ( P s < .05).
Discussion Strategies to increase Black older adult participation in AD research may include disseminating additional study information and return of results.
Declaration of Interest None of the investigators have a conflict of interest. JE receives support from VA IK HX002283, NIA P30AG072976, and NIA P30AG010133. AJP receives support from NIA (NIA U01 AG057195) and Alzheimer’s Association (LDRFP-21-818464). SW receives support from multiple NIA grants (K23AG062555, P30AG072976, P30AG010133, and R21AG074179) and the VA for clinical services. She receives book royalties from APPI and DSMB consultant fees (total less than $2000/year). AJS receives support from multiple NIH grants (P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, and U01 AG068057 and U01 AG072177). He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor); Bayer Oncology (Scientific Advisory Board); Eisai (Scientific Advisory Board); Siemens Medical Solutions USA, Inc. (Dementia Advisory Board); Springer-Nature Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging and Behavior).
### Competing Interest Statement
None of the investigators have a conflict of interest. JE receives support from VA IK HX002283, NIA P30AG072976, and NIA P30AG010133. AJP receives support from NIA (NIA U01 AG057195) and Alzheimer's Association (LDRFP-21-818464). SW receives support from multiple NIA grants (K23AG062555, P30AG072976, P30AG010133, and R21AG074179) and the VA for clinical services. She receives book royalties from APPI and DSMB consultant fees (total less than $2000/year). AJS receives support from multiple NIH grants (P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, and U01 AG068057 and U01 AG072177). He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor); Bayer Oncology (Scientific Advisory Board); Eisai (Scientific Advisory Board); Siemens Medical Solutions USA, Inc. (Dementia Advisory Board); Springer-Nature Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging and Behavior).
### Funding Statement
This research was supported by the National Institutes of Health's National Institute on Aging, P30AG10133-30 (A.J.S., S.W.), P30 AG072976-01 (A.J.S.; S.W.; J.E.), and R01 AG019771 (A.J.S.) and by the Alzheimer's Association, LDRFP-21-818464 (S.W.; A.J.P.). This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Institute on Aging or the Alzheimer;s Association. This material was supported with resources and the use of facilities at the Roudebush VAMC. This research also does not represent the official view of the VA Medical Center. The contents do not represent the views of VA or the United States Government.
### Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Indiana University gave ethical approval of this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
All data produced in the present study are available upon reasonable request to the authors
更多查看译文
关键词
white older adults,alzheimers,motivators,older adults,participation
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要